ArticleScientific reports2016
Uterus-targeted liposomes for preterm labor management: studies in pregnant mice.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- An evolutionary genomic perspective on preterm birth, genome editing, and pregnancy in the human species.Frontiers in genome editing · 2026Review
- Preventing Preterm Birth: The Search for Tocolytic Synergism.Reproductive sciences (Thousand Oaks, Calif.) · 2025Review
- Therapeutic nanoparticle safety in pregnancy: Bridging knowledge gaps with environmental insights and a translational roadmap.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
- The Application of Nano Drug Delivery Systems in Female Upper Genital Tract Disorders.Pharmaceutics · 2024Review
- Nanomedicine for Maternal and Fetal Health.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Actively Targeted Nanomedicines: A New Perspective for the Treatment of Pregnancy-Related Diseases.Reproductive sciences (Thousand Oaks, Calif.) · 2024Review
- EGFR-targeted ionizable lipid nanoparticles enhance in vivo mRNA delivery to the placenta.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions.ACS nano · 2024Article
- Rethinking the application of nanoparticles in women's reproductive health and assisted reproduction.Nanomedicine (London, England) · 2024Review
- Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review.Therapeutic delivery · 2024Review
- Nanomedicine strategies to improve therapeutic agents for the prevention and treatment of preterm birth and future directions.Nanoscale advances · 2023Review
- The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.International journal of molecular sciences · 2022Review
- Nanotechnologies in Obstetrics and Cancer during Pregnancy: A Narrative Review.Journal of personalized medicine · 2022Review
- Placental Models for Evaluation of Nanocarriers as Drug Delivery Systems for Pregnancy Associated Disorders.Biomedicines · 2022Review
- Targeted Delivery of Epidermal Growth Factor to the Human Placenta to Treat Fetal Growth Restriction.Pharmaceutics · 2021Article
- Targeted drug delivery for maternal and perinatal health: Challenges and opportunities.Advanced drug delivery reviews · 2021Review
- Oxytocin and Bone: Review and Perspectives.International journal of molecular sciences · 2021Review
- Nanotherapeutic-directed approaches to analgesia.Trends in pharmacological sciences · 2021Review
- Landscape of Preterm Birth Therapeutics and a Path Forward.Journal of clinical medicine · 2021Review
- Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preterm labor caused by uterine contractions is a major contributor to neonatal morbidity and mortality. Treatment intended to reduce uterine contractions include tocolytic agents, such as indomethacin. Unfortunately, clinically used tocolytics are frequently inefficient and cross the placenta causing fetal side effects. Here we show for the first time in obstetrics the use of a targeted nanoparticle directed to the pregnant uterus and loaded with a tocolytic for reducing its placental passage and sustaining its efficacy. Nanoliposomes encapsulating indomethacin and decorated with clinically used oxytocin receptor antagonist were designed and evaluated in-vitro, ex-vivo and in-vivo. The proposed approach resulted in targeting uterine cells in-vitro, inhibiting uterine contractions ex-vivo, while doubling uterine drug concentration, decreasing fetal levels, and maintaining the preterm birth rate in vivo in a pregnant mouse model. This promising approach opens new horizons for drug development in obstetrics that could greatly impact preterm birth, which currently has no successful treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.